SynCore Biotechnology Co.,Ltd
Taipei Exchange 4192.TWO
SynCore Biotechnology Co.,Ltd Price to Book Ratio (P/B) on January 13, 2025: 3.06
-
SynCore Biotechnology Co.,Ltd 52-week high Price to Book Ratio (P/B) is 4.10 on August 02, 2024, which is 34.17% above the current Price to Book Ratio (P/B).
-
SynCore Biotechnology Co.,Ltd 52-week low Price to Book Ratio (P/B) is 3.06 on January 13, 2025, which is 0.00% below the current Price to Book Ratio (P/B).
-
SynCore Biotechnology Co.,Ltd average Price to Book Ratio (P/B) for the last 52 weeks is 3.54.
| Date | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield | Price to Earnings Ratio (P/E) |
|---|
| CEO | Mr. Chih-Wen Lee |
| IPO Date | Aug. 29, 2013 |
| Location | |
| Headquarters | 84 Chung Shan Road |
| Employees | 40 |
| Sector | Health Care |
| Industries | |
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts; and SB04,an conventional drug for the treatment of age-related macular degeneration that is in Phase II clinical trials. In addition, the company provides SB05-EndoTAG, an conventional drug for pancreatic cancer and triple-negative breast cancer that is in Phase III clinical trials. Further, it distributes cameras under the epiCam name that is used in recording the progress of ophthalmology diseases. The company has partnerships with Medigene AG and MacuCLEAR Inc.; Sinphar Pharmaceutical Co., Ltd.; and The National Health Research Institutes. SynCore Biotechnology Co.,Ltd was incorporated in 2008 and is headquartered in Yilan City, Taiwan. The company is a subsidiary of Sinphar Pharmaceutical Co., Ltd.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email